Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oragenics Inc OGEN

Healthcare Biotechnology
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for... see more

Recent & Breaking News (NYSEAM:OGEN)

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

GlobeNewswire 6 days ago

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

GlobeNewswire October 18, 2024

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

GlobeNewswire October 9, 2024

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

GlobeNewswire October 8, 2024

Oragenics, Inc. Announces Closing of Public Offering

GlobeNewswire September 5, 2024

Oragenics, Inc. Announces Pricing of Public Offering

GlobeNewswire September 4, 2024

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

GlobeNewswire August 21, 2024

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

GlobeNewswire August 16, 2024

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

GlobeNewswire August 14, 2024

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

GlobeNewswire August 12, 2024

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

GlobeNewswire August 8, 2024

Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients

GlobeNewswire July 10, 2024

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

GlobeNewswire June 27, 2024

Oragenics, Inc. Announces Closing of Public Offering

GlobeNewswire June 26, 2024

Oragenics, Inc. Announces Pricing of Public Offering

GlobeNewswire June 25, 2024

Oragenics, Inc. Announces Proposed Public Offering

GlobeNewswire June 24, 2024

Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance

GlobeNewswire June 20, 2024

Oragenics Appoints William "Frank" Peacock MD as Chief Clinical Officer

GlobeNewswire May 22, 2024

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

GlobeNewswire May 17, 2024

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial

GlobeNewswire May 16, 2024